Central nervous system infection and cutaneous lymphadenitis due to Mycobacterium kansasii in an immunocompetent patient.
Tabatabaei
N
N
Stout
J
J
Goldschmidt-Clermont
P
P
Murdoch
D
D
D000368:Aged; D000995:Antitubercular Agents / Q000627:therapeutic use; D020806:Central Nervous System Bacterial Infections / Q000382:microbiology*; D024901:Drug Resistance, Multiple, Bacterial; D004977:Ethambutol / Q000627:therapeutic use; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D008199:Lymphadenitis / Q000382:microbiology*; D008297:Male; D009165:Mycobacterium Infections, Nontuberculous / Q000503:physiopathology*; D019909:Mycobacterium kansasii / Q000472:pathogenicity*; D012293:Rifampin / Q000627:therapeutic use; D017192:Skin Diseases, Bacterial / Q000382:microbiology*
D000995:Antitubercular Agents; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin